A $65M Biotech Cluster, Two Pharma Owners, and Four Regional Bank Buyers All See the Same Week: Clinical Value and Credit Quality Are Both Being Priced at Fear Levels
Forbion committed $64.8M to Braveheart Bio alongside its CEO, CFO, and two directors buying the same day. Simultaneously, Redmile and Sanofi doubled into Attovia, and four regional bank insiders bought independently. Insiders across biotech and financials are signaling that the market is applying distress pricing to businesses running at fundamentally healthier levels.




















